全国《国家处方药价格透明度法》要求与实施分析。

IF 4.8 2区医学 Q1 HEALTH CARE SCIENCES & SERVICES

Milbank Quarterly Pub Date : 2025-05-30 DOI:10.1111/1468-0009.70023

Hannah Rahim, Aaron S Kesselheim

{"title":"全国《国家处方药价格透明度法》要求与实施分析。","authors":"Hannah Rahim, Aaron S Kesselheim","doi":"10.1111/1468-0009.70023","DOIUrl":null,"url":null,"abstract":"Policy Points A total of 21 states have passed drug price transparency laws with the goals of creating accountability around drug pricing and facilitating the development of policy solutions to address high prices. These laws vary in design but often require manufacturers to report the wholesale acquisition cost of drugs above a certain threshold for new drugs or of drugs that undergo a price increase above a certain margin, along with other data such as the manufacturer's costs. Initial findings suggest these laws may have contributed toward informing policymaking based on newly available public information but do not appear to have affected drug prices.","PeriodicalId":49810,"journal":{"name":"Milbank Quarterly","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"National Analysis of the Requirements and Implementation of State Prescription Drug Price Transparency Laws.\",\"authors\":\"Hannah Rahim, Aaron S Kesselheim\",\"doi\":\"10.1111/1468-0009.70023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Policy Points A total of 21 states have passed drug price transparency laws with the goals of creating accountability around drug pricing and facilitating the development of policy solutions to address high prices. These laws vary in design but often require manufacturers to report the wholesale acquisition cost of drugs above a certain threshold for new drugs or of drugs that undergo a price increase above a certain margin, along with other data such as the manufacturer's costs. Initial findings suggest these laws may have contributed toward informing policymaking based on newly available public information but do not appear to have affected drug prices.\",\"PeriodicalId\":49810,\"journal\":{\"name\":\"Milbank Quarterly\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Milbank Quarterly\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/1468-0009.70023\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Milbank Quarterly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1468-0009.70023","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

摘要

共有21个州通过了药品价格透明度法，其目标是围绕药品定价建立问责制，并促进制定解决高价格问题的政策解决方案。这些法律的设计各不相同，但通常要求制造商报告超过一定阈值的新药或价格上涨超过一定边际的药物的批发收购成本，以及制造商成本等其他数据。初步调查结果表明，这些法律可能有助于根据新获得的公共信息为政策制定提供信息，但似乎并未影响药品价格。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

National Analysis of the Requirements and Implementation of State Prescription Drug Price Transparency Laws.

Policy Points A total of 21 states have passed drug price transparency laws with the goals of creating accountability around drug pricing and facilitating the development of policy solutions to address high prices. These laws vary in design but often require manufacturers to report the wholesale acquisition cost of drugs above a certain threshold for new drugs or of drugs that undergo a price increase above a certain margin, along with other data such as the manufacturer's costs. Initial findings suggest these laws may have contributed toward informing policymaking based on newly available public information but do not appear to have affected drug prices.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Milbank Quarterly 医学-卫生保健

CiteScore

9.60

自引率

3.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Milbank Quarterly is devoted to scholarly analysis of significant issues in health and health care policy. It presents original research, policy analysis, and commentary from academics, clinicians, and policymakers. The in-depth, multidisciplinary approach of the journal permits contributors to explore fully the social origins of health in our society and to examine in detail the implications of different health policies. Topics addressed in The Milbank Quarterly include the impact of social factors on health, prevention, allocation of health care resources, legal and ethical issues in health policy, health and health care administration, and the organization and financing of health care.